SCHEMBL1641900

SCHEMBL1641900

O=C(Nc1cccc(-c2ncsc2-c2ccnc(Cl)n2)c1)c1c(F)cccc1F

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 2/20 0.47
TP53 P04637 1/20 0.47
PKMYT1 Q99640 1/20 0.46
BRAF P15056 1/20 0.45
IGF1R P08069 8/20 0.44
EGFR P00533 6/20 0.44
ERBB2 P04626 6/20 0.44
KDR P35968 3/20 0.43
AURKB Q96GD4 3/20 0.43
PRKD3 O94806 2/20 0.43
MAP4K4 O95819 2/20 0.43
LCK P06239 2/20 0.43
FYN P06241 2/20 0.43
CSF1R P07333 2/20 0.43
RET P07949 2/20 0.43
MAP4K2 Q12851 2/20 0.43
STK3 Q13188 2/20 0.43
TAOK1 Q7L7X3 2/20 0.43
MAP4K5 Q9Y4K4 2/20 0.43
AURKA O14965 2/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1642023 0.88 LCLAT1 (0.47) MAPTTP53BRAFEGFRERBB2
SCHEMBL12726561 0.86 BRAF (0.54) PKMYT1BRAFIGF1REGFRERBB2
SCHEMBL1640456 0.86 MAPT (0.47) MAPTTP53PKMYT1BRAFIGF1R
SCHEMBL1640498 0.86 BRAF (0.49) MAPTTP53PKMYT1BRAFIGF1R
SCHEMBL13120712 0.86 MAPT (0.53) MAPTTP53PKMYT1EGFRKDR
SCHEMBL1639294 0.85 BRAF (0.49) MAPTTP53PKMYT1BRAFIGF1R
SCHEMBL1641904 0.85 BRAF (0.51) MAPTTP53PKMYT1BRAFIGF1R
SCHEMBL1641081 0.83 BRAF (0.49) MAPTTP53PKMYT1BRAFIGF1R
SCHEMBL1641468 0.83 BRAF (0.48) MAPTTP53PKMYT1BRAFIGF1R
SCHEMBL1642030 0.83 BRAF (0.64) MAPTTP53PKMYT1BRAFIGF1R

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110098296-A1 Thiazole And Oxazole Kinase Inhibitors GLAXOSMITHKLINE LLC 2011-04-28 US disclosed
US-20110098296-A1 Thiazole And Oxazole Kinase Inhibitors GLAXOSMITHKLINE LLC 2011-04-28 US disclosed
US-20110098296-A1 Thiazole And Oxazole Kinase Inhibitors GLAXOSMITHKLINE LLC 2011-04-28 US disclosed
EP-2231625-A1 THIAZOLE AND OXAZOLE KINASE INHIBITORS GlaxoSmithKline LLC (US) 2010-09-29 EP disclosed
WO-2009076140-A1 THIAZOLE AND OXAZOLE KINASE INHIBITORS SMITHKLINE BEECHAM CORPORATION (US) 2009-06-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110098296-A1 Thiazole And Oxazole Kinase Inhibitors PDXK, MAP3K1, MAP4K2 MAPT 1402/4885TP53 754/4885PKMYT1 485/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.